Crossject Société Anonyme (ALCJ.PA)
EUR 2.0
(1.01%)
EUR 2.0
(1.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -6.13 Million EUR | -32.09% |
| 2022 | -13.89 Million EUR | -25.59% |
| 2021 | -11.06 Million EUR | -1336.46% |
| 2020 | 894.73 Thousand EUR | 109.04% |
| 2019 | -9.9 Million EUR | -1790.07% |
| 2018 | -523.83 Thousand EUR | -153.69% |
| 2017 | 975.67 Thousand EUR | 445.94% |
| 2016 | -282.03 Thousand EUR | -416.33% |
| 2015 | 89.15 Thousand EUR | 103.34% |
| 2014 | -2.67 Million EUR | -18117.83% |
| 2013 | 14.82 Thousand EUR | -94.6% |
| 2012 | 274.22 Thousand EUR | -54.74% |
| 2011 | 605.91 Thousand EUR | 132.69% |
| 2010 | -1.85 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -718 Thousand EUR | 0.0% |
| 2023 Q2 | -6.34 Million EUR | 0.0% |
| 2023 FY | -18.35 Million EUR | -32.09% |
| 2023 Q4 | -4.14 Million EUR | 0.0% |
| 2022 FY | -13.89 Million EUR | -25.59% |
| 2022 Q2 | -7.02 Million EUR | 0.0% |
| 2022 Q4 | -6.86 Million EUR | 0.0% |
| 2021 Q4 | -5.38 Million EUR | 0.0% |
| 2021 FY | -11.06 Million EUR | -1336.46% |
| 2021 Q2 | -5.67 Million EUR | 0.0% |
| 2020 Q2 | -254.97 Thousand EUR | 0.0% |
| 2020 Q4 | 1.14 Million EUR | 0.0% |
| 2020 FY | 894.73 Thousand EUR | 109.04% |
| 2019 Q4 | 981.03 Thousand EUR | 0.0% |
| 2019 FY | -9.9 Million EUR | -1790.07% |
| 2019 Q2 | -5.54 Million EUR | 0.0% |
| 2018 Q2 | -1.51 Million EUR | 0.0% |
| 2018 FY | -523.83 Thousand EUR | -153.69% |
| 2018 Q4 | -3.05 Million EUR | 0.0% |
| 2017 FY | 975.67 Thousand EUR | 445.94% |
| 2017 Q4 | -1.67 Million EUR | 0.0% |
| 2017 Q2 | -1.66 Million EUR | 0.0% |
| 2016 Q4 | -1.85 Million EUR | 0.0% |
| 2016 Q2 | -1.57 Million EUR | 0.0% |
| 2016 FY | -282.03 Thousand EUR | -416.33% |
| 2015 Q4 | -1.14 Million EUR | 0.0% |
| 2015 Q2 | -1.83 Million EUR | 0.0% |
| 2015 FY | 89.15 Thousand EUR | 103.34% |
| 2014 Q2 | -1.25 Million EUR | 0.0% |
| 2014 FY | -2.67 Million EUR | -18117.83% |
| 2014 Q4 | -1.41 Million EUR | 0.0% |
| 2013 Q1 | -230.27 Thousand EUR | -0.0% |
| 2013 FY | 14.82 Thousand EUR | -94.6% |
| 2013 Q4 | -731.1 Thousand EUR | -217.49% |
| 2013 Q3 | -230.27 Thousand EUR | -21.2% |
| 2013 Q2 | -190 Thousand EUR | 17.49% |
| 2012 FY | 274.22 Thousand EUR | -54.74% |
| 2012 Q1 | 68.55 Thousand EUR | -0.0% |
| 2012 Q2 | 68.55 Thousand EUR | 0.0% |
| 2012 Q3 | 68.55 Thousand EUR | -0.0% |
| 2012 Q4 | -230.27 Thousand EUR | -435.9% |
| 2011 Q4 | 68.55 Thousand EUR | -54.74% |
| 2011 FY | 605.91 Thousand EUR | 132.69% |
| 2011 Q3 | 151.47 Thousand EUR | -0.0% |
| 2011 Q2 | 151.48 Thousand EUR | 0.0% |
| 2011 Q1 | 151.47 Thousand EUR | -0.0% |
| 2010 Q1 | -463.39 Thousand EUR | -0.0% |
| 2010 Q4 | 151.48 Thousand EUR | 132.69% |
| 2010 Q3 | -463.39 Thousand EUR | -0.0% |
| 2010 FY | -1.85 Million EUR | 0.0% |
| 2010 Q2 | -463.39 Thousand EUR | 0.0% |
| 2009 Q4 | -463.39 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Safe Orthopaedics SA | 4.1 Million EUR | 249.415% |
| Spineway SA | 1.55 Million EUR | 495.551% |
| Amplitude Surgical SA | 37.2 Million EUR | 116.49% |
| Sartorius Stedim Biotech S.A. | 1.23 Billion EUR | 100.497% |
| EssilorLuxottica Société anonyme | 16.07 Billion EUR | 100.038% |
| bonyf N.V. | 26.41 Thousand EUR | 23326.319% |